华熙生物跌2.01%，成交额5718.28万元，主力资金净流出991.88万元

Core Viewpoint - Huaxi Biological experienced a stock price decline of 2.01% on January 16, with a trading price of 46.42 yuan per share and a total market capitalization of 22.36 billion yuan [1] Group 1: Stock Performance - Since the beginning of the year, Huaxi Biological's stock price has increased by 6.27%, with a 0.41% rise over the last five trading days and a 6.10% increase over the last 20 days, while it has decreased by 13.56% over the last 60 days [2] - As of November 20, the number of shareholders for Huaxi Biological is 30,100, a decrease of 0.62% from the previous period, with an average of 16,014 circulating shares per person, which is an increase of 0.62% [2] Group 2: Financial Performance - For the period from January to September 2025, Huaxi Biological reported a revenue of 3.163 billion yuan, a year-on-year decrease of 18.36%, and a net profit attributable to shareholders of 252 million yuan, down 30.29% year-on-year [2] - The company has distributed a total of 1.138 billion yuan in dividends since its A-share listing, with 528 million yuan distributed over the past three years [3] Group 3: Shareholder Structure - As of September 30, 2025, the top ten circulating shareholders of Huaxi Biological include several ETFs, with notable reductions in holdings: E Fund's Shanghai Stock Exchange Science and Technology Innovation Board 50 ETF decreased by 1.0136 million shares, while Huaxia's ETF decreased by 0.38234 million shares [3] - Other significant shareholders also saw reductions, including Hong Kong Central Clearing Limited, which decreased its holdings by 0.31229 million shares [3]